PDCD1 and lymphoma: Inflamed lymphomas such as cHL tumors have shown increased sensitivity to anti-PD-1 blockade therapy and are characterized by an unusually high immune cell infiltrate, an inflammatory PD-L1+ TME, a high mutational burden (95) and genetic alterations that facilitate cancer immunoediting escape including aberrant MHC class I molecule expression (96).